Prosecution Insights
Last updated: April 19, 2026

Examiner: CANDELARIA, JULIANA IRENE

Tech Center 1600 • Art Units: 1634 1641 1674 1677

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
17
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

4.8%
§101 Eligibility
12.9%
§102 Novelty
35.5%
§103 Obviousness
35.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18340917 NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE Non-Final OA Regeneron Pharmaceuticals, Inc.
18115285 BIOREACTOR FOR ANTIBODY PRODUCTION Non-Final OA Regeneron Pharmaceuticals, Inc.
17918830 MODIFIED CCR POLYPEPTIDES AND USES THEREOF Non-Final OA Regeneron Pharmaceuticals, Inc.
18342930 LUNG CANCER MODELING USING NORMAL LUNG ORGANOID WITH LUNG CANCER CELLS Non-Final OA THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18344973 MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS Non-Final OA JANSSEN BIOTECH, INC.
18345951 TMPRSS KNOCKOUT SWINE HAVING A REDUCED SUSCEPTIBILITY TO INFLUENZA Non-Final OA Kansas State University Research Foundation
17996573 SIRPa Deficient Macrophages for Treating Cancer Non-Final OA Georgia State University Research Foundation, Inc.
18348292 TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT Non-Final OA CREATIVE MEDICAL TECHNOLOGIES, INC.
18350892 Method for Obtaining Cultures of Mesenchymal Stem Cells (MSCs) from the Perivascular Space of the Umbilical Cord Vessel Non-Final OA BAOSHENGTANG BIOTECH CO., LTD.
17999987 COMPOSITIONS AND METHODS FOR NEGATIVE SELECTION OF NAIVE T AND B CELLS WITH A SINGLE ANTIBODY Non-Final OA BioMagnetic Solutions LLC
18135945 CHIMERIC ADAPTOR PROTEINS AND METHODS OF REGULATING GENE EXPRESSION Non-Final OA FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month